North China Pharmaceutical Company Ltd.

Shanghai Stock Exchange 600812.SS

North China Pharmaceutical Company Ltd. Operating Income for the year ending December 31, 2023: USD 22.04 M

North China Pharmaceutical Company Ltd. Operating Income is USD 22.04 M for the year ending December 31, 2023, a -82.58% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

North China Pharmaceutical Company Ltd. Operating Income for the year ending December 31, 2022 was USD 126.47 M, a 3.07% change year over year.
North China Pharmaceutical Company Ltd. Operating Income for the year ending December 31, 2021 was USD 122.70 M, a -1.14% change year over year.
North China Pharmaceutical Company Ltd. Operating Income for the year ending December 31, 2020 was USD 124.12 M, a 7.51% change year over year.
North China Pharmaceutical Company Ltd. Operating Income for the year ending December 31, 2019 was USD 115.45 M, a 287.59% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

Shanghai Stock Exchange: 600812.SS

North China Pharmaceutical Company Ltd.

CEO	Mr. Xin Yan Liu
IPO Date	Jan. 14, 1994
Location	China
Headquarters	No. 388, Heping East Road
Employees	10,159
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Personal Care Pet Food Plastics

Description

North China Pharmaceutical Company Ltd. operates as a chemical pharmaceutical company in China. It primarily offers anti-infective drugs, comprising APIs, and intermediates and their preparations; biotechnology drugs; cardiovascular and immunomodulators; vitamins health consumer products; and bio-agricultural and veterinary drugs. North China Pharmaceutical Company Ltd. was founded in 1953 and is based in Shijiazhuang, China.

Key trends

Past 5 years